SG10202105499WA - Antibodies Against Fcrn And Use Thereof - Google Patents

Antibodies Against Fcrn And Use Thereof

Info

Publication number
SG10202105499WA
SG10202105499WA SG10202105499WA SG10202105499WA SG10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA
Authority
SG
Singapore
Prior art keywords
antibodies against
against fcrn
fcrn
antibodies
Prior art date
Application number
SG10202105499WA
Other languages
English (en)
Inventor
Christopher Tenhoor
Arumugam Muruganandam
Robert Charles Ladner
Clive Wood
Alan J Bitonti
James Stattel
Kevin Mcdonnell
Liming Liu
Jennifer DUMONT
Aaron Sato
Original Assignee
Dyax Corp
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp, Bioverativ Therapeutics Inc filed Critical Dyax Corp
Publication of SG10202105499WA publication Critical patent/SG10202105499WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
SG10202105499WA 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof SG10202105499WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4815208P 2008-04-25 2008-04-25
US4850008P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
SG10202105499WA true SG10202105499WA (en) 2021-07-29

Family

ID=41203902

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202105499WA SG10202105499WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof
SG10201804513WA SG10201804513WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof
SG10201804513WA SG10201804513WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof

Country Status (17)

Country Link
US (10) US8273351B2 (de)
EP (3) EP2310415B8 (de)
JP (5) JP6106854B2 (de)
KR (4) KR20190104432A (de)
CN (3) CN104479017A (de)
AU (1) AU2009238605B2 (de)
BR (2) BR122021026834B1 (de)
CA (2) CA3131470A1 (de)
ES (1) ES2650804T3 (de)
HK (2) HK1160868A1 (de)
IL (2) IL208846A (de)
MX (1) MX2010011679A (de)
NZ (1) NZ589451A (de)
SG (3) SG10202105499WA (de)
TW (3) TWI593423B (de)
WO (1) WO2009131702A2 (de)
ZA (1) ZA201007873B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
JP6032818B2 (ja) 2011-02-25 2016-11-30 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ抗体
ES2748583T3 (es) 2011-06-02 2020-03-17 Dyax Corp Proteínas de unión al receptor Fc
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
BR122019023952B1 (pt) * 2011-09-30 2022-09-20 Chugai Seiyaku Kabushiki Kaisha Biblioteca de anticorpos dependentes de concentração de íon
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
SG11201405137QA (en) * 2012-02-24 2014-12-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
ES2671631T3 (es) 2012-04-23 2018-06-07 Nrl Pharma, Inc. Proteína de fusión de lactoferrina y método para la preparación de la misma
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
MY171407A (en) 2013-03-15 2019-10-11 Affibody Ab New polypeptides
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
MX2015014017A (es) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Variante de la region fc.
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
EP3892294A1 (de) * 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
KR102452173B1 (ko) * 2013-12-24 2022-10-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn 길항제 및 사용방법
AU2015249666A1 (en) * 2014-04-25 2016-11-17 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
ES2952583T3 (es) * 2014-04-30 2023-11-02 Hanall Biopharma Co Ltd Anticuerpo de unión a FcRn para tratar enfermedades autoinmunes
CA2914595C (en) * 2014-05-19 2022-12-13 F. Hoffmann-La Roche Ag Method for producing antibodies using ovine b-cells and uses thereof
RU2725442C2 (ru) 2014-09-17 2020-07-02 Аффибоди Аб Новые полипептиды
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR102483016B1 (ko) * 2015-01-30 2023-01-03 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
EP3253778A1 (de) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antikörper mit einer ionenkonzentrationsabhängigen antigenbindenden domäne, fc-region-varianten, il-8-bindende antikörper und verwendungen davon
AU2016262100B2 (en) * 2015-05-12 2021-10-14 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CA2996299C (en) 2015-08-24 2022-09-27 University Of Cincinnati Methods and compositions for the detection of fc receptor binding activity of antibodies
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2020092155A1 (en) * 2018-10-31 2020-05-07 Bioatla, Llc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
DK3491025T3 (da) * 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
JP7142915B2 (ja) 2016-10-28 2022-09-28 株式会社Ｓ＆Ｋバイオファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
RU2020100880A (ru) * 2017-06-15 2021-07-15 Юсб Биофарма Срл Способ лечения иммунной тромбоцитопении
KR20200098604A (ko) 2017-12-13 2020-08-20 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) * 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
BR112021007092A2 (pt) 2018-10-16 2021-08-03 UCB Biopharma SRL método para o tratamento de miastenia grave
SG11202112010RA (en) 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
EP4007605A4 (de) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Fcrn-antikörper und verfahren zur verwendung davon
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR102507515B1 (ko) * 2020-08-26 2023-03-08 이화여자대학교 산학협력단 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
CN116234827A (zh) * 2021-09-03 2023-06-06 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
CN116047054A (zh) * 2023-03-08 2023-05-02 江西赛基生物技术有限公司 用于检测血小板抗体的试剂盒及其制备方法和使用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3875456T3 (de) 1987-11-09 1998-06-10 Becton Dickinson Co Verfahren zur Analyse hämatopoietischer Zellen in einer Probe.
EP0768377A1 (de) 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
EP0940468A1 (de) 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
EP1978033A3 (de) 1995-04-27 2008-12-24 Amgen Fremont Inc. Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4046354B2 (ja) * 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
ES2373110T3 (es) 1997-01-21 2012-01-31 The General Hospital Corporation Selección de proteínas usando fusiones de arn-proteína.
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
PT1438400E (pt) 2001-10-01 2009-09-10 Dyax Corp Vectores de apresentação eucarióticos de cadeias múltiplas e suas utilizações
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
EP1660128A4 (de) 2003-08-08 2009-01-21 Univ New York State Res Found Anti-fcrn-antikörper zur behandlung von auto/allo-immunzuständen
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2606378A1 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
US20090092507A1 (en) * 2005-08-05 2009-04-09 Ramirez Jr Emilio A Fluid pump systems
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
ES2748583T3 (es) * 2011-06-02 2020-03-17 Dyax Corp Proteínas de unión al receptor Fc
JP7422659B2 (ja) * 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
CA3101462A1 (en) * 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
WO2020236695A1 (en) * 2019-05-17 2020-11-26 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases

Also Published As

Publication number Publication date
EP3348573B1 (de) 2020-04-22
EP2310415B8 (de) 2017-12-13
TWI547287B (zh) 2016-09-01
US20130078262A1 (en) 2013-03-28
WO2009131702A3 (en) 2010-02-18
JP6499132B2 (ja) 2019-04-10
HK1207089A1 (en) 2016-01-22
EP2310415B1 (de) 2017-10-11
CN102149729B (zh) 2014-08-20
IL208846A0 (en) 2011-01-31
KR20110044729A (ko) 2011-04-29
JP6106854B2 (ja) 2017-04-05
IL208846A (en) 2015-09-24
TWI453031B (zh) 2014-09-21
US20160222108A1 (en) 2016-08-04
EP3348573A1 (de) 2018-07-18
CN108467431A (zh) 2018-08-31
KR20160079912A (ko) 2016-07-06
AU2009238605B2 (en) 2014-11-06
BR122021026834B1 (pt) 2022-11-08
KR102072896B1 (ko) 2020-02-03
WO2009131702A2 (en) 2009-10-29
TW201509430A (zh) 2015-03-16
KR20190104432A (ko) 2019-09-09
TWI593423B (zh) 2017-08-01
CN102149729A (zh) 2011-08-10
US9260520B2 (en) 2016-02-16
US8815246B2 (en) 2014-08-26
SG10201804513WA (en) 2018-07-30
JP5989159B2 (ja) 2016-09-07
US20130045218A1 (en) 2013-02-21
US20160222112A1 (en) 2016-08-04
US20090324614A1 (en) 2009-12-31
EP3670538A1 (de) 2020-06-24
IL241091A0 (en) 2015-11-30
WO2009131702A9 (en) 2010-09-23
CA3131470A1 (en) 2009-10-29
TW201010720A (en) 2010-03-16
HK1160868A1 (en) 2012-08-17
JP2011523351A (ja) 2011-08-11
MX2010011679A (es) 2011-05-23
US20160222110A1 (en) 2016-08-04
CA2722082A1 (en) 2009-10-29
NZ589451A (en) 2012-07-27
CN104479017A (zh) 2015-04-01
JP2019162105A (ja) 2019-09-26
ZA201007873B (en) 2012-02-29
US20160222109A1 (en) 2016-08-04
US20160194397A1 (en) 2016-07-07
KR101837329B1 (ko) 2018-03-09
KR101634719B1 (ko) 2016-06-29
US20140248287A1 (en) 2014-09-04
EP2310415A2 (de) 2011-04-20
JP2022115960A (ja) 2022-08-09
CA2722082C (en) 2021-11-09
US20160222111A1 (en) 2016-08-04
ES2650804T3 (es) 2018-01-22
BRPI0910622A2 (pt) 2020-03-10
SG196839A1 (en) 2014-02-13
AU2009238605A1 (en) 2009-10-29
KR20170122286A (ko) 2017-11-03
IL241091B (en) 2018-02-28
US8273351B2 (en) 2012-09-25
TW201630626A (zh) 2016-09-01
JP2017029149A (ja) 2017-02-09
JP2015143230A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
IL241091A0 (en) Antibodies to fcrn and their use
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
EP2236604A4 (de) Anti-nr10-antikörper und verwendung davon
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
HK1209130A1 (en) Immunoglobulin variants and uses thereof
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
HK1156326A1 (en) Anti-hepcidin-25 selective antibodies and uses thereof
IL207129A0 (en) Ron antibodies and uses thereof
IL236237A (en) Tmem154 antibodies and their segments and uses
IL212040A0 (en) Hepatitis c antibodies and uses thereof
HK1203206A1 (en) Antibody and use thereof
GB0807018D0 (en) Antibodies and treatment
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2388320A4 (de) Anti-hs6st2-antikörper und verwendung davon
EP2322610A4 (de) Anti-human-clcp1-antikörper und seine anwendung
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
GB0812277D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof